# US 2004/0073000 A1 · Genes and proteins, and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0073000 A1
- Document ID: US20040073000A1
- Status: Published application
- Kind: A1
- Application number: 10/362,327
- Filed: 2003-10-02
- Published: 2004-04-15
- Earliest claimed: 2000-08-24
- Inventors: Jonathan Douglas Lane; Martin John Glenton Hughes; Joseph David Santangelo
- Web page: https://patentgrep.com/patent/US20040073000A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- A61P 31/04: Antibacterial agents
- C07K 14/22: from Neisseriaceae (F)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/53: {DNA (RNA) vaccination}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A series of genes from Neisseria meningitidis are shown to encode products which are targets for immunisation. The identification of these genes therefore allows vaccines to be produced and other therapeutic products.

## Claims

### Claim 1

A peptide encoded by a gene including any of the nucleotide sequences identified herein as SEQ ID NOS. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 and 33, of N. meningitidis, or a homologue thereof in a Gram-negative bacterium, or a functional fragment thereof, for therapeutic or diagnostic use.

### Claim 2 (depends on 1)

A peptide according to claim 1, wherein the homologue has at least 40% sequence similarity or identity at the peptide or nucleotide level.

### Claim 3 (depends on 1, 2)

A peptide according to claim 1 or claim 2, wherein the homologue has at least 60% sequence similarity or identity at the peptide or nucleotide level.

### Claim 4

A peptide according to any preceding claim, wherein the homologue has at least 90% sequence similarity or identity at the peptide or nucleotide level.

### Claim 5 (depends on 1)

A peptide according to claim 1, comprising any of the amino acid sequences defined herein as SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 and 34.

### Claim 6

A polynucleotide encoding a peptide according to any preceding claim, for therapeutic or diagnostic use.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A host transformed to express a peptide according to any of claims 1 to 5.

### Claim 8 (depends on 1)

A microorganism comprising a mutation that disrupts the expression of any of the nucleotide sequences defined in claim 1.

### Claim 9 (depends on 8)

A microorganism according to claim 8, wherein the mutation is insertional inactivation or a gene deletion.

### Claim 10 (depends on 8, 9)

A microorganism according to claim 8 or claim 9, wherein the microorganism is Neisseria meningitidis.

### Claim 11 (depends on 8, 9, 10)

A microorganism according to any of claims 8 to 10, comprising a mutation in a second nucleotide sequence.

### Claim 12 (depends on 8, 9, 10, 11)

A microorganism according to any of claims 8 to 11, for therapeutic or diagnostic use.

### Claim 13 (depends on 1, 2, 3, 4, 5)

A vaccine comprising a peptide according to any of claims 1 to 5, or the means for its expression.

### Claim 14 (depends on 1, 2, 3, 4, 5)

An antibody raised against a peptide according to any of claims 1 to 5.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7)

Use of a product according to any of claims 1 to 7, in a screening assay.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

Use of a product according to any of claims 1 to 12, for the manufacture of a medicament for use in the treatment or prevention of a condition associated with infection by Neisseria or Gram-negative bacteria.
